Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 14/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CCL5 | P13501 | 8/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980163 | 0.88 | CCR5 (0.46) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL5235161 | 0.86 | CCR5 (0.54) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL5238345 | 0.86 | CCR5 (0.53) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL5234516 | 0.84 | CCR5 (0.51) | CCR5KCNH2CYP2D6 | |
| SCHEMBL5231310 | 0.81 | CCR5 (0.49) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL5233830 | 0.80 | CCR5 (0.50) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL4906571 | 0.79 | CCR5 (0.53) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL3592590 | 0.76 | CCR5 (0.55) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL6012135 | 0.74 | CCR5 (0.63) | CCR5KCNH2CYP3A4CYP2D6CCL5 | |
| SCHEMBL6012136 | 0.74 | CCR5 (0.63) | CCR5KCNH2CYP3A4CYP2D6CCL5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648871-B1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | US | disclosed |
| EP-1648871-A1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005007629-A1 | PIPERIDINE OR 8-AZA-BICYCLO[3.2.1]OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | CCR5, CCR2, CCR7 | CCR5 1/4885KCNH2 1750/4885CYP3A4 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.